In the past few months, proposals from the United States Patent and Trademark Office (“USPTO”) have drawn the attention of organizations, companies, and individuals in the life sciences space. Together, the proposals have the potential to significantly affect life sciences companies’ patent and regulatory strategies in the United States—particularly, how they engage in patent prosecution before the USPTO and navigate the drug approval process with the United States Food & Drug Administration (“FDA”). The period for public comment on these proposals recently closed, and the industry now awaits the USPTO’s decisions.  

Read more here: Ongoing Initiatives at the USPTO and FDA and Their Potential Impact on the Life Sciences Industry in the United States, Kristen Riemenschneider, Jeff Jay, Jake Silvers (freshfields.us)

See all Member News